Biolocity is proud to be named a 2020 Capital Challenge Grant recipient. This award from the U.S. Economic Development Administration (EDA) provides us with the opportunity to launch a new, early-stage life science fund that can bridge the critical gap in technology development from bench to scalable business. We aim to help entrepreneurs build successful businesses and create sustainable jobs in the region by funding technology-driven start-ups in the life sciences.
Five research innovations from Emory University and Georgia Tech selected for Biolocity Launch.
The Biolocity team is excited to announce the faculty-lead innovations selected to participate in the newest cohort of Biolocity Launch! In addition to receiving funding to support commercialization milestones, awardees join a year-long collaboration with consultants and business advisors for project management and longitudinal coaching to accelerate the development of their patient-impacting technologies.
Each year, Biolocity opens an intensive, multi-stage application process that provides applicants with the opportunity to receive pitch coaching, market assessments, and competitive analysis needed for commercial success. Faculty work with entrepreneur advisors to de-risk their technology at each application stage before final acceptance into the program by an oversight committee comprised of venture capitalists, entrepreneurs, clinicians, biomedical engineers, and university technology transfer experts.
Below are the select projects included in this year’s cohort:
- Dynamic Sampling Platform: This platform technology aims to provide simple, accurate, and low-cost quality monitoring for cell therapy bioreactors. Principal Investigators: Andrei Fedorov, PhD, Georgia Tech, Edwin Horwitz, MD, Emory University, and Mason Chilmonczyk, PhD, Georgia Tech.
- Focused Cryo: A cryoablation system designed to aid in targeting peripheral nerves in a highly precise manner. The platform has applications in metabolic syndromes, obesity, hypertension, diabetes, and chronic pain. Principal Investigators: David Prologo, MD, FSIR, Emory University.
- NanoCliq: A vaccine technology that leverages protein nanoparticle platform to prevent the onset of Leishmaniasis, a fatal disease that currently has no vaccine available. Principal Investigator: M.G. Finn, PhD, Georgia Tech.
- New Therapeutic for Inflammatory Bowel Disease (IBD): The development of an LRH-1 agonist drug which increases innate steroid production specifically at the site of inflammation in the gut. Principal Investigators: Nathan Jui, PhD, Emory University, Eric Ortlund, PhD, Emory University, and John Calvert, PhD, Emory University.
- Twice Therapeutics: A two-step method that can deliver long-lasting gene therapies to diseased tissues without re-engineering viruses. Principal Investigators: James Dahlman, PhD, Georgia Tech and Eric Sorscher, MD, Emory University
“We are fortunate in this current climate to continue to be able to provide funding that will assist the commercialization of these promising technologies,” says Manuel Kingsley, interim director of the Biolocity Program. “While research may look different this year, the passion these innovators have for improving healthcare delivery is unwavering as is our team’s commitment to their advancement. We look forward to working with each awardee to support their technology development.”
Funding and commercialization support provided by Biolocity is used to bridge the gap in development between early-stage university research and its path to the market. If you are interested in commercialization guidance for a device, therapeutic, or platform technology with the ability to positively impact human health, schedule a meeting here.
To learn more about Biolocity’s funding and partnership opportunities, visit www.Biolocity.org.
Biolocity’s newest offering in partnership with Emory School of Law and Professor Nicole Morris provides complimentary counseling and materials to Emory University and Georgia Tech innovators and startup companies.
Schedule an appointment or view the full list of areas of support using the below link.
The Biolocity team recently teamed up with fellow Biomedical Advanced Research and Development Authority (BARDA) DRIVe Network Accelerators New Orleans BioInnovation Center and First Flight Venture Center to host the Southeast COVID-19 Innovation Showcase. This event highlighted BARDA’s current funding opportunities along with pitches from technology teams providing solutions related to the COVID-19 pandemic. Learn more about the event and related funding opportunities here.
Please note that the areas of interest for BARDA DRIVe’s funding opportunities change over time. Please visit https://drive.hhs.gov/ for the most up-to-date areas of interest.
Congratulations to Shawna Khouri, Biolocity Managing Director, for being selected from a pool of over 400 applicants for a new program designed to recognize the achievements of Georgia Institute of Technology alumni who are improving the human condition.
ATLANTA, JULY 15, 2020 — The Georgia Tech Alumni Association has announced 40 distinguished honorees who have innovated industries and positively impacted communities across the globe. In its first year, more than 250 individuals were nominated by colleagues, peers, and Georgia Tech faculty this April.
Shawna Khouri is a life science entrepreneur and funder who has catalyzed and grown Atlanta’s life science start-up ecosystem. Khouri shares that “Being a Georgia Tech alumna is something to be proud of, but being included amongst such an impressive list of peers is simply humbling.”
In its inaugural year, the 2020 class includes Olympian and breast cancer survivor Chaunté Lowe; founder of the Algorithmic Justice League (and one of Shawna Khouri’s freshman dorm-mates), Joy Buolamwini, whose research on algorithmic bias in artificial intelligence (AI) has led to policy and industry changes in addressing AI harms; and Maithili Appalwar, who founded Avana to address the alarming rate of suicides among farmers in Yavatmal, a district in Maharashtra, India by working with more than 10,000 farmers to conserve more than 50 billion liters of water.
“I am amazed and humbled by the accomplishments of these innovators and trendsetters. They epitomize the focus that our Georgia Tech alumni have to make the world a better place,” shares Dene Sheheane, president of the Georgia Tech Alumni Association.
Those nominated must have completed at least one semester at Georgia Tech, be under the age of 40 as of June 30, 2020, and have made an impact in their profession or community, spanning all industries and sectors. A committee of 26 faculty, staff, and volunteer leaders, who collectively represented all Georgia Tech colleges, scored each nominee using a 25-point rubric. Selection Committee member Bert Reeves, MGT 2000, State Representative in the Georgia House of Representatives, expressed that, “I was blown away at the nearly impossible task of scoring the applicants. These are folks who are not just impacting their community and state, but in some cases, their country and the entire world. It is truly inspiring to see the innovation and passion that our alumni are contributing to many of the greatest issues our world faces today.”
A list of all 40 honorees is available here.
About the Georgia Tech Alumni Association
The Georgia Tech Alumni Association, chartered in 1908, is an exclusive network of more than 172,000 worldwide tied together by their experience at Georgia Tech. Through the Association, Tech alumni gain immediate access to its extensive, global alumni network, as well as numerous alumni programs and services designed to enrich both careers and lives. The Georgia Tech Alumni Association is a participation-driven non-profit corporation governed by a board of alumni volunteers. Since 1947, the Association’s Roll Call program has raised money to financially support Tech’s academic mission, a tradition that has transformed the Institute into the place it is today. Learn more at www.gtalumni.org.
Biolocity is an incubator at Emory University & Georgia Institute of Technology focused on advancing life science technologies to the market. In October 2019, Biolocity was selected to join the BARDA DRIVe Accelerator Network. In this role, we have been working with BARDA to identify companies and innovative technologies that help address 21st-century health security threats, with a recent focus on COVID-19. In response to the Coronavirus public health emergency, we received numerous questions from members of our ecosystem and we saw an opportunity to share BARDA DRIVe’s perspective as well as their funding and partnership opportunities.
Biolocity recently sat down with our partners at BARDA DRIVe to learn more about BARDA-specific response to COVID-19 and how our ecosystem can help address this public health emergency.
Dr. Sandeep Patel, DRIVe Director, offered his thoughts.
Tell us a little bit about BARDA and DRIVe. What makes DRIVe unique within BARDA?
The Biomedical Advanced Research and Development Authority or BARDA, as we are known, is part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and devices needed to combat health security threats, including pandemics like COVID-19, and save lives. Our development goal is always regulatory approval, licensure, or clearance.
Within BARDA, DRIVe, the Division of Research, Innovation and Ventures, accelerates the development and availability of transformative technologies and approaches, particularly to challenges that span all health security threats, like early detection of infection and personal notification to act, control, and treat infections, or even sepsis. We have some unique funding capabilities and responsive timelines that increase the agility of BARDA to respond to rapidly emerging threats with innovative technologies. We partner with companies and teams offering solutions to a broad range of national health security threats. DRIVe partnering approaches vary depending on the project. BARDA has two currently open solicitations, our EZ-BAA for awards under $749K and our BARDA BAA for more advanced projects.
What is the role of DRIVe in the BARDA response to COVID-19?
DRIVe has been 100% focused on developing and delivering needed capabilities to address COVID-19. We temporarily shifted our usual DRIVe areas of interest in order to focus our EZ BAA intensively on COVID-19 medical countermeasure development at this time. Not surprisingly, many of the technologies that we were already supporting in our DRIVe portfolio to Solve Sepsis or identify early infection were nicely suited to also address SARS-CoV-2 and COVID-19. To add to these efforts, we are soliciting proposals and quickly making awards for the development of SARS-CoV-2 diagnostic tests, vaccines, and advanced pharmaceutical manufacturing technologies. In the three months since we broadened our aperture and published the EZ BAA COVID-19 special instructions, we’ve received and processed more applications than we did over an entire year at a normal operating pace. Incredibly, we’ve been able to maintain our rapid review turnaround cycles, awarding the first COVID-19 diagnostics contracts in as few as twelve days.
How can innovators keep apprised of BARDA’s areas of interest related to COVID-19?
Follow us @BARDA on LinkedIn and check out our evolving portfolio on medicalcountermeasures.gov. To support ongoing U.S. government COVID-19 medical countermeasure development efforts, BARDA is pleased to offer our EZ-BAA and BARDA BAA. These open solicitations seek abstract or white paper submissions for select COVID-19 medical countermeasures. For up-to-date information on the BARDA COVID-19-focused areas of interest, you can visit our COVID-19 EZ BAA website or the BARDA website, which also describes a number of other ways to engage with us one-on-one. Interested parties can also request a CoronaWatch Meeting. This is an interagency, single point of entry portal for vaccines, therapeutics, diagnostic assays, or other products and services related to COVID-19. These market research submissions allow ASPR, BARDA, NIH, NIAID, FDA, CDC, and DoD colleagues to also become aware of potential COVID-19 projects in development.
With the range of Federal funding resources in response to COVID-19, how does BARDA’s interest vary from or complement others like the NIH, DoD, and FDA?
We are working closely with our HHS agencies—NIH, FDA, and CDC—and other federal partners to leverage our efforts when able and in this way build the most robust portfolio of products and technologies to address our shared areas of interest. HHS, DoD, Homeland Security, and others have pandemic preparedness programs that collaborate with each other, from early research to advanced development, procurement, and deployment. During a public health emergency response, it is vital that we are in constant communication with our federal partners along the acquisition spectrum. BARDA, NIH, CDC, and the FDA complement each other across the research, development, procurement, and deployment of medical countermeasures. BARDA typically focuses on the advanced research and development of medical countermeasures, partnering with industry to provide funding and expertise to pursue FDA approval, clearance or authorization, and ultimately make available safe and effective medical countermeasures to protect Americans. For the COVID-19 response, each agency is working more closely and coordinated on medical countermeasure development than we have ever seen in the past. To be successful, it is critical that we are all coordinated and hyper-focused on accelerating the development of life-saving medicines, vaccines, and diagnostics to halt this pandemic.
What is the best way for innovators to engage BARDA if they have a solution that will impact the response to COVID-19?
We encourage them to reach out to our national network of BARDA DRIVe Accelerator Network members, including Biolocity, to receive a quick consultation on the fit and area of interest of your technology with current BARDA partnership opportunities. Through our accelerator network partnerships, DRIVe is decentralizing innovation across the country with regional accelerators, selected through a competitive process, to identify promising innovation and provide wraparound technical and business development support services.
Anyone developing a technology is encouraged to submit a request with a short description of their technology to the intergovernmental COVID-19 CoronaWatch program at medicalcountermeasures.gov. Submissions to this portal are reviewed by BARDA and our federal government partners, relevant technologies that meet an agency’s needs are invited to have a market research meeting. As needs emerge and change in response to the COVID-19 pandemic agencies have the ability to query previous submissions. The interagency COVID-19 CoronaWatch program was launched specifically to help companies streamline the process of preparing their proposals. Before companies would have to reach out separately to multiple agencies however, with this portal they only have to submit one request which is accessible to all interested U.S. government agencies which saves them valuable time and resources.
How can applicants tell if their technology is a better fit for the BARDA EZ-BAA funding mechanism or the regular BARDA BAA?
A great start would be to consult with one of the accelerators in our BARDA DRIVe Accelerator Network. These accelerators were selected through a competitive process to work with us as extensions of ourselves, scouting and coaching potential applicants for BARDA’s areas of interest. We work with them regularly and they are up to speed on the latest information about our EZ BAA and BARDA BAA, and COVID-19 focus areas.
The best way is to review the EZ-BAA and BARDA BAA solicitations themselves, where companies can find in-depth information applicable to their technology. Typically, technologies submitted to the BAA are more advanced in technological readiness than technologies submitted to the EZ-BAA.
What are some of the common traits of successful awardees for both the EZ-BAA and BAA?
BARDA has worked successfully with companies of all sizes and scopes, from small entrepreneurial groups to biotech groups to large multinational organizations. So, there really is not a set of “common” traits for awardees, it varies in terms of what companies are offering and the technological readiness of their products and technologies. Both of these BAAs describe a wide variety of our product interest areas aimed at getting the COVID-19 response capacity developed and deployed as quickly as possible but also looking toward long-term solutions to this problem that will be around for some time and strengthen our everyday health system. The criteria are explained in each BAA, but again our Accelerator Network can help and you can always reach out to us too, we are happy to answer questions.
How does BARDA typically engage with awardees? How has this changed as part of the COVID-19 response?
The process itself hasn’t changed. BARDA works side by side with its industry and start-up partners. BARDA is not just a funding organization, we provide project support, technical expertise, and oversight throughout the partnership. BARDA partners can access a deep pool of product development, regulatory, manufacturing as well as non-clinical and clinical subject matter experts throughout the partnership. BARDA program teams meet regularly with partners to ensure projects are running smoothly and issues are being addressed as quickly as possible.
Anything else we should know about the BARDA & DRIVe COVID-19 opportunities for partnership?
Yes: please follow us on social media (@BARDA) for all the latest on the COVID-19 response and our other mission areas. You can also visit our COVID-19 Portfolio Page to see what companies we have partnered with to end the pandemic. And one more thing – we are hiring! You can see recent postings on BARDA’s Twitter @BARDA and BARDA LinkedIn pages as well as on USAJOBS.gov.
Biolocity is a philanthropic, multi-institutional network supporting university medical technology commercialization in the southeast. Through a combination of investment, project management, consulting, and educational programming, Biolocity provides early-stage, patient impacting technologies with the resources needed to reach critical commercialization milestones.